ApoAI MP can increase SOD, CAT, GSH-Px activity, up-regulate GSH content, and reduce the level of malondialdehyde, a marker of lipid peroxidation; and it was suggested that the therapeutic mechanism of ApoAI MP on PD may be related to alleviating oxidative stress and reducing the damage of ROS and H2O2. Here, APOA1 is linked to Parkinson disease.